Fresenius SE & Co. KGaA

Earnings Release • Nov 13, 2011

Factsheet Q3 / 2011

COMPANY PROFILE

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. More than 145,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	Q1 – 3 / 11	2010	2009	2008
Sales and Earnings
Sales	12,089	15,972	14,164	12,336
EBIT	1,862	2,418	2,054	1,727 1
Net income 1, 2	565	660	514	450
Earnings per ordinary share in € 1	3.47	4.08	3.18	2.85
Balance sheet and cash fl ow
Total assets	24,707	23,577	20,882	20,544
Non-current assets	17,871	17,142	15,519	15,466
Equity 3	10,049	8,844	7,491	6,943
Equity ratio 3	41%	38%	36%	34%
Net debt / EBITDA4	2.7	2.6	3.0	3.6
Investments 5	1,388	1,402	931	4,617
Operating cash fl ow	1,156	1,911	1,553	1,074
Operating cash fl ow in % of sales	9.6%	12.0%	11.0%	8.7%
Profi tability
EBIT margin	15.4%	15.1%	14.5%	14.0% 1
Return on equity after taxes (ROE) 4, 6	12.8%	13.3%	12.1%	10.5%
Return on operating assets (ROOA) 4	11.2%	11.6%	10.5%	9.8%
Return on invested capital (ROIC) 4	9.0%	8.9%	8.2%	7.3%
Employees (December 31)	145,118	137,552	130,510	122,217

¹ 2008 before special items from the APP acquisition;

2011, 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.

2 Net income attributable to Fresenius SE & Co. KGaA 3

Equity including noncontrolling interest 4 2008 pro forma APP Pharmaceuticals and excluding special items from the APP-acquisition

5 Investments in property, plant and equipment and intangible assets, acquisitions

6 2011, 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR.

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA. In addition, with the Fresenius Biotech Fresenius is active in research and development in the fi eld of antibody therapies.

		100%	Fresenius Biotech
30%	100%	100%	77%
Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed

BUSINESS SEGMENTS

			Q1 – 3 / 2011		2010
€ in millions		Sales	EBIT	Sales	EBIT
		6,735	1,058	9,091	1,451
		2,950	613	3,672	737
		1,950	195	2,520	235
		480	22	713	41

• ▶ Fresenius Medical Care is the world's leading provider of services and products for patients with chronic kidney failure. As of September 30, 2011, Fresenius Medical Care was treating 228,239 patients in 2,874 dialysis clinics.
• ▶ Fresenius Kabi offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
• ▶ Fresenius Helios is one of the largest private hospital operators in Germany. HELIOS owns 64 hospitals, including fi ve maximum care hospitals in Berlin-Buch, Erfurt, Krefeld, Schwerin and Wuppertal. HELIOS treats more than 2 million patients per year, thereof approximately 650,000 inpatients, and operates about 19,000 beds.
• ▶ Fresenius Vamed offers engineering and services for hospitals and other health care facilities.
• ▶ Fresenius Biotech develops innovative therapies with trifunctional antibodies for the treatment of cancer.

SALES BY BUSINESS SEGMENT

Q1 – 3 2011: €12.1 billion

SALES BY REGION

FRESENIUS SHARE / ADR

	Ordinary share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of ordinary shares (October 31, 2011)	163,041,829
Market capitalization (October 31, 2011)	€10.9 billion

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Matu rity
Fresenius Finance B. V.	XS0240918218	€500	5.00%	2013
Fresenius Finance B. V.	XS0240919372	€650	5.50%	2016
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015

Bonds of Fresenius Medical Care can be found under www.fmc-ag.com\Credit Relations.

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX DAX Fresenius ordinary share

SHARE PERFORMANCE 1

1 month	- 8.1 %
3rd quarter	- 6.9 %
1 year	+ 13.5 %
5 years	+ 44.8 %
10 years	+ 123.4 %

Effective date / closing price: September 30, 2011

DEVELOPMENT ORDINARY SHARE DIVIDENDS IN €

1993 2002 1994 1995 1996 1997 1998 1999 2000 2001 2003 2004 2005 2006 2007 2008 2009 2010

GROUP OUTLOOK 2011

Sales growth (in constant currency)	~ 6%
Net income, growth (in constant currency) 1	15% – 18% 2
Capital expenditure	~ 5% of group sales

Net income attributable to Fresenius SE & Co. KGaA; adjusted for the

effects of the mark-to-market accounting of the MEB and the CVR. Upper half of range expected

1

2

For the outlook of the business segments please see the Investor News of November 2, 2011.

FINANCIAL CALENDAR

	Dates
Report on Fiscal Year 2011	February 21, 2012
Report on 1st quarter 2012	May 3, 2012
Annual General Meeting, Frankfurt / Main	May 11, 2012
Capital Market Day Fresenius Kabi	June 12, 2012
Report on 1st half 2012	August 1, 2012
Report on 1st – 3rd quarter 2012	October 31, 2012

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fl uctuations, uncertainties in litigation or investigative proceedings, and the availability of fi nancing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA Registered Offi ce: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE Registered Offi ce: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Dr. Ulf M. Schneider (Chairman), Rainer Baule, Dr. Francesco De Meo, Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick

CONTACT

Fresenius SE & Co. KGaA Birgit Grund Telephone: ++49 61 72 6 08-24 85

61352 Bad Homburg v. d. H.

Senior Vice President Telefax: ++49 61 72 6 08-24 88 Investor Relations e-mail: ir-fre@fresenius.com Else-Kröner-Straße 1 Internet: www.fresenius.de

Targets 2011

.
$15\% - 18\%$ 2
.
$\sim$ 5% of group sales